Beyond LDL-C control, there is growing recognition of the importance of addressing atherogenic dyslipidemia, characterized by elevated triglyceride and apolipoprotein B levels, especially in the context of increasing obesity and insulin resistance. This evidence concerns the gene APOB and obesity due to melanocortin 4 receptor deficiency.